Core Operating Subsidiaries



One of the largest steel fabrication and erection companies in the U.S.
Offers full suite of integrated steel construction and professional services
92.5% ownership
FY17 Revenue: $579.0m
FY17 Adjusted EBITDA: $51.6m

Marine Services


Leading provider of subseacable installation, maintenance, and protection in telecom, offshore power, and oil & gas
JV’s with Huawei Marine Networks & S.B. Submarine Systems (China Telecom)
72.5% ownership
FY17 Revenue: $169.5m
FY17 Adjusted EBITDA: $44.0m



Premier distributor of natural gas motor fuel throughout the U.S.
Currently own or operate ~42 natural gas fueling stations throughout United States
67.7% ownership
FY17 Revenue: $16.4m
FY17 Adjusted EBITDA: $2.9m



One of the largest International wholesale telecom service companies
Global sales presence
Internal and scalable offshore back office operations
100% ownership
FY17 Revenue: $701.9m
FY17 Adjusted EBITDA: $6.9m

Core Financial Subsidiaries




Platform to invest in long-term care (LTC) portfolio of assets
Initially acquired American Financial Group’s LTC assets
Ring Fenced Liabilities – No Parent Guarantees
100% ownership
~$68.7m of statutory surplus
~$85.4m total adjusted capital
~$1.5b cash & invested assets
Recently closed acquisition of Humana’s $2.4b LTC assets:
~$155 - $175 million pro-forma statutory surplus; ~$185 - $205 million pro-forma total adjusted capital

Early Stage and Other Holdings

parallax background

Life Sciences


HC2’s Pansend Life Sciences Segment Is Focused on the Development of Innovative Healthcare Technologies and Products
  • Recently completed sale to Janssen Biotech, Inc. (Johnson & Johnson) for up to $1.04 billion (2Q18); $8m total investment
  • 76% equity ownership of company focused on immunotherapy; Oncolytic virotherapy for treatment of solid cancer tumors
  • 74% equity ownership of dermatology company focused on lightening and brightening skin
  • Founded by Pansend in partnership with Mass. General Hospital and inventors Dr. Rox Anderson, Dieter Manstein and Dr. Henry Chan
  • Over $20 billion global market
  • Received Food and Drug Administration approval for the R2 Dermal Cooling System (4Q16)
  • Received Food and Drug Administration approval for second generation R2 Dermal Cooling System (2Q17)
  • 80% equity ownership in the company with unique knee replacements based on technology from Dr. Peter Walker, NYU Dept. of Orthopedic Surgery and one of the pioneers of the original Total Knee.
  • “Mini-Knee” for early osteoarthritis of the knee; “Anatomical Knee” – A Novel Total Knee Replacement
  • Strong patent portfolio
  • 50% equity ownership in the company with unique technology and device for monitoring of real-time kidney function
  • Current standard diagnostic tests measure kidney function are often inaccurate and not real-time
  • MediBeacon’s Optical Renal Function Monitor will be first and only, non-invasive system to enable real-time, direct monitoring of renal function at point-of-care
  • $3.5 billion potential market
  • Successfully completed a key clinical study of its unique, real-time kidney monitoring system on subjects with impaired kidney function at Washington University in St. Louis. (1Q17)
  • Profitable technology and product development company
  • Areas of expertise include medical devices, homeland security, imaging systems, sensors, optics, fluidics, robotics and mobile healthcare
  • Located in Silicon Valley and Boston area with over 90,000 square feet of working laboratory and incubator space
  • Contract R&D market growing rapidly
  • Customers include Fortune 500 companies and start-ups
parallax background


HC2 Broadcasting Holdings

Capitalizing on Over-the-Air broadcast opportunities
  • HC2 Broadcasting Holdings Inc., a subsidiary of HC2 Holdings, has strategically acquired broadcast assets across the United States
  • HC2’s broadcast vision is to capitalize on the opportunities to bring valuable content to more viewers over-the-air and position the company for a changing media landscape